Cash from Operations (Quarterly) Chart

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
September 30, 2026 -2.902M
June 30, 2026 -2.692M
March 31, 2026 -3.43M
December 31, 2025 -6.619M
September 30, 2025 -8.317M
June 30, 2025 -14.49M
March 31, 2025 -14.48M
December 31, 2024 -15.51M
September 30, 2024 -15.60M
June 30, 2024 -13.67M
March 31, 2024 -15.52M
December 31, 2023 -10.38M
September 30, 2023 -10.49M
June 30, 2023 -10.18M
March 31, 2023 -12.70M
December 31, 2022 -13.01M
September 30, 2022 -12.25M
June 30, 2022 -12.26M
March 31, 2022 -11.52M
December 31, 2021 -10.72M
Date Value
September 30, 2021 -8.102M
June 30, 2021 -7.752M
March 31, 2021 -8.587M
December 31, 2020 -5.988M
September 30, 2020 -6.592M
June 30, 2020 -9.451M
March 31, 2020 -3.926M
December 31, 2019 -5.894M
September 30, 2019 -6.957M
June 30, 2019 -7.183M
March 31, 2019 -6.868M
December 31, 2018 -7.05M
September 30, 2018 -7.452M
June 30, 2018 -6.053M
March 31, 2018 -5.478M
December 31, 2017 -6.369M
September 30, 2017 -2.357M
June 30, 2017 -7.062M
March 31, 2017 -6.349M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Indaptus Therapeutics, Inc. -1.245M
Cue Biopharma, Inc. -10.08M
Yarrow Bioscience, Inc. -89.96M
Faeth Therapeutics, Inc. -13.00M
Pyxis Oncology, Inc. -16.29M